MedDataX Logo

Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers

NCT ID: NCT03246516

Last Updated: 2025-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

258 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-01

Study Completion Date

2025-02-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the role of socioeconomic and individual factors in the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) in oeso-gastric cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Reducing the time between the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) is essential to improve the vital prognosis and quality of life of patients. Recent data suggest that some sociocognitive and emotional determinants may explain patient delay from a complementary point of view. The main objective of this study is to assess whether, in oeso-gastric cancer, patient delay is linked to these sociocognitive and emotional factors, in addition to previously known factors.

We intend to include in this study 300 patients with a not yet treated oeso-gastric cancer diagnosed in one of 10 health centres in the North of France region. The collected data will be analysed to underline the differences between patients who consulted a doctor earlier versus those who consulted later with a cut off at 8 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oesophageal Carcinoma Gastric Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Questionnaire

Auto and hetero questionnaire

Group Type EXPERIMENTAL

Questionnaire

Intervention Type OTHER

Auto and hetero questionnaires:

* STAI Y B, State-Trait Anxiety Inventoriage
* Brief COPE
* RHHI-24, Revised Health Hardiness Inventory
* IPQ-R, Illness Perception Questionnaire

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaire

Auto and hetero questionnaires:

* STAI Y B, State-Trait Anxiety Inventoriage
* Brief COPE
* RHHI-24, Revised Health Hardiness Inventory
* IPQ-R, Illness Perception Questionnaire

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age ≥ 18 years
* oesophageal, oeso-gastric junction or gastric cancer non treated cancer
* patient informed of his diagnosis
* speak fluent french

Exclusion Criteria

* history of cancer
* psychological history
* patient under guardianship-
* fortuitous diagnosis of cancer
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Lille Nord de France

OTHER

Sponsor Role collaborator

University Hospital, Lille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Guillaume Piessen, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Lille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre hospitalier de Béthune

Béthune, , France

Site Status

Centre Hospitalier de Boulogne sur mer

Boulogne-sur-Mer, , France

Site Status

Centre hospitalier de Calais

Calais, , France

Site Status

centre Léonard de Vinci

Dechy, , France

Site Status

Centre d 'oncologie Dunkerquois

Dunkirk, , France

Site Status

CHRU, Hôpital Claude Huriez

Lille, , France

Site Status

Centre oscar Lambret

Lille, , France

Site Status

Centre hospitalier de Roubaix

Roubaix, , France

Site Status

Centre Hospitalier de Seclin

Seclin, , France

Site Status

Centre hospitalier de valenciennes

Valenciennes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2015-A01986-43

Identifier Type: OTHER

Identifier Source: secondary_id

2015_74

Identifier Type: -

Identifier Source: org_study_id